Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Payables (2022 - 2025)

Historic Payables for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to $1.1 million.

  • bioAffinity Technologies' Payables rose 258.46% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 258.46%. This contributed to the annual value of $1.2 million for FY2024, which is 9163.38% up from last year.
  • As of Q3 2025, bioAffinity Technologies' Payables stood at $1.1 million, which was up 258.46% from $1.2 million recorded in Q2 2025.
  • Over the past 5 years, bioAffinity Technologies' Payables peaked at $1.5 million during Q1 2025, and registered a low of $146537.0 during Q1 2023.
  • Over the past 4 years, bioAffinity Technologies' median Payables value was $827407.0 (recorded in 2023), while the average stood at $753016.5.
  • As far as peak fluctuations go, bioAffinity Technologies' Payables surged by 38864.02% in 2024, and later skyrocketed by 258.46% in 2025.
  • bioAffinity Technologies' Payables (Quarter) stood at $345042.0 in 2022, then skyrocketed by 75.28% to $604789.0 in 2023, then surged by 91.63% to $1.2 million in 2024, then dropped by 7.06% to $1.1 million in 2025.
  • Its Payables was $1.1 million in Q3 2025, compared to $1.2 million in Q2 2025 and $1.5 million in Q1 2025.